STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4153 by analyst upside · 2026-08-13
TWST
Twist Bioscience Corporation
Healthcare · Market Cap $8B · P/E 0x
ANALYST PRICE TARGET
-15.9%
implied upside to consensus target
Current Price $125.21
Consensus Target $105.3
Bull Target $120.0
Bear Target $36.0
Analysts Covering 10
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
6
Hold
2
Sell
0
52-Week Low $23.3
52-Week High $125.66
YTD Return +286.6%
FUNDAMENTALS
Market Cap $8B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.23
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $432M
Profit Margin -31.7%
52-WEEK RANGE
52-Week Low $23.3
52-Week High $125.66
Current Price $125.21
Bear Target $36.0
Bull Target $120.0
● Now $125.21 ● Target $105.3
TRADING DATA
Avg Volume 1.8M
YTD Return +286.6%
Analyst Count 10
Consensus Buy
Upside to Target -15.9%
Last Updated 2026-08-13

ANALYST SUMMARY

Twist Bioscience Corporation (TWST) is currently trading at $125.21 with a Wall Street consensus price target of $105.3, which is 15.9% below the current price over the next 12 months. 10 analysts currently cover TWST, with a consensus rating of Buy - 80% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $120.0, while the most cautious has a target of $36.0.

TWST operates in the Healthcare sector with a market capitalisation of $8B. The stock is up 286.6% year-to-date and is currently trading near the upper end of its 52-week range of $23.3 – $125.66.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TWST, with each firm's 90-day track record across all stocks we track. See full firm rankings →

TD Cowen - Reiterated
Buy → Buy 2026-06-15 Building track record
Canaccord Genuity ● Initiated
Buy 2026-06-15 Building track record
Piper Sandler ● Initiated
Overweight → Overweight 2026-06-11 14% win rate (7 calls)
Leerink Partners ↑ Upgrade
Market Perform → Outperform 2026-05-05 29% win rate (7 calls)
Barclays - Reiterated
Overweight → Overweight 2026-05-05 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-05-05 62% win rate (8 calls)
Baird - Reiterated
Outperform → Outperform 2026-05-05 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-04-14 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
57
out of 100
Coverage depth
18/30
Consensus clarity
17/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →